Seoul-based pharmaceutical manufacturer Lotte Biologics has begun construction of a new $3.3 billion bio plant located at the Songdo Bio Campus in Incheon, South Korea. The investment will establish three facilities on the company’s over 2.1 million-sq.-ft. site. Work starts with bio plant 1, a mammalian cell culture facility which will introduce the initial 120,000 liters of production capacity, scaling to 360,000 liters upon completion of additional facilities. “The journey of Lotte Biologics, commencing here in Songdo, is poised not only to become a future growth engine for Lotte Group but also to reshape Korea's biotech industry landscape,” said Lotte Chairman Dong-Bin Shin. “Our unwavering commitment is to contribute significantly to the successful establishment of Songdo's bio cluster, thereby propelling Korea to the forefront of the global biotech arena.” For the company, the goal of this project is to position Lotte Biologics as a leading Contract Development and Manufacturing Organization (CDMO) by 2030. In total, this project will create 37,000 direct and indirect jobs in the region, the company says. In Site Selection’s March 2024 issue, aerotropolis expert Dr. John Kasarda and co-author Michael Chen said the Incheon region encompassing Songdo represents “a paragon of airport, airport city and aerotropolis development.”
|